index
中 文 ENGLISH
HomeAbout UsCharacteristic businessAgent BrandCareersContact UsSite MapOnline communications
    Products Search
 
    Product Catalog
Nucleic acids
 Nucleic acid purchase  
Nucleic acid amplification  
Nucleic acid analysis   
Nucleic acid isolation and purification
Proteins
 Protein purchase   
Protein isolation & purification
 Protein expression  
Protein analysis
  Others
Cell
 Cell purchase    Cell isolation
 Cell cultivation and
microorganism fermentation
 Cell analysis
Consumables
    Electronic journals
 
 
 
Your position:  Home >> Industry News >> 
none
2015 Global life sciences outlook
2015-3-26

2015 Global life sciences outlook

Adapting in an era of transformation

                                                                                                                                               From: Deloitte

                                                                                                                                               Date: 2015-3-26

Overview and outlook

The extended nature of life sciences product development mandates that sector stakeholders adopt a long-term focus to strategic planning, portfolio management, and market expansion. However, organizations must also prepare for and react to near-term challenges and opportunities. Four major trends are expected to capture the sectors attention in 2015: searching for innovation and growth; changing regulatory and risk environment; preserving and building shareholder value; and preparing for the next wave. The resulting challenges and opportunities can be both global and market-specific. Read on to learn more about these trends and suggested considerations for stakeholders.

 

Global life sciences sector trends in 2015

Searching for innovation & growth

As with venture capital funding, transactions have been skewing toward fewer, bigger deals. Also, for business reasons, companies operating on a global scale are looking to restructure in ways that allow for the efficient use of foreign capital. Partnerships and informal collaborations also will comprise an important part of the picture as companies continue to grapple with a rapidly shifting landscape, grow distribution networks, and leverage previous investments. New insurance and payment models, rapidly changing consumer demographics, and an explosion of technology-based treatment innovations are driving both horizontal and vertical M&A activity.

 

Acclimating to a changing regulatory & risk environment

Todays global life sciences sector has been likened to the financial services industry of five to 10 years ago, with product safety issues, security & privacy breaches, intellectual property (IP) tangles, inappropriate marketing practices, and corruption incidents pushed to the forefronteach of which can result in government fines, product recalls, adverse media coverage, brand recognition damage and revenue/market share losses. In the past, regulatory fines have been relatively small; however, they are growing in size and significance; precisely what happened in the banking world, which today sees a very different story in the magnitude of fines, sanctions, and public condemnation.

 

Preserving & building shareholder value

Global life sciences companies deal daily with pricing pressures, generics competition, margin erosion, supply chain issues, and regulatory constraints, all of which can limit their ability to grow revenues. On the cost side, rising R&D expenses, marketing & sales outlays, and general operating cost increases can exert pressure on gross margins. Still, companies are expected to preserve and build shareholder value.

Fortunately, improving R&D productivity, recent increases in NME approvals, and expanding product pipelinescombined with ongoing cost containmentsuggest that fundamentals are aligning to increase shareholder value. Operational transparency and addressing risks and improving processes within finance & accounting (F&A) operationsvia treasury solutions and services such as controls testing, balance sheet integrity, gross-to-net (GtN) forecasting, cost management, and reporting optimizationcan help to foster shareholder confidence. In addition, optimizing the mix of sales, marketing, and market-access expenditures at the local market level is essential to increasing shareholder value. However, a number of external and internal forces have the potential to move the needle up or down; among them, price controls & access, generics, and supply chain operations.

 

Preparing for the next wave

Government, provider, and payor efforts to control health care spending, reduce variations in care, and engage consumers in self-care are among the driving forces behind the health care industrys transition from volume-based to value-based care (VBC). As part of this transition, comparative effectiveness research (CER) which compares different interventions for a health condition based on real-world effectiveness rather than controlled efficacy is becoming a major factor in a treatments market uptake. Products not proving to be comparatively effective may struggle to generate demand or attain reimbursement. Payors are using CER to manage formularies, providers are leveraging it to guide clinical decisions, and governments are supporting (and, in some cases, funding) CER.

 

The number and diversity of life sciences customer segments suggest that one-size-fits-all approaches to understanding and addressing their needs will be ineffective in an era of transformation. The importance of physicians as the sole influencer in prescription volume or product purchase is rapidly diminishing, as the industry explores new engagement models with an ever-evolving set of customers.

As growth in developed markets slows, life sciences companies are expected to continue expanding their presence in emerging markets through acquisitions and joint ventures. Key growth drivers include an increase in wealth and income levels, increasing government and consumer awareness about the benefits of a good health care system, and a trend towards healthier lifestyles.

 

 
Previous:>> Hepatitis C: Key Molecules That Inhibit Viral Production Identified
  网友评论: (只显示最新10条. 评论内容只代表网友观点, 与本站立场无关!)
  • 游客『mike11』于2018-4-16 23:28:24发表评论:
  • 评分: 3分
    Rhn4GA https://www.genericpharmacydrug.com
  • 游客『tmumdndewlc』于2018-4-16 4:05:18发表评论:
  • 评分: 3分
    fhm4QY  <a href="http://fjquegqyhnju.com/">fjquegqyhnju</a>, [url=http://gulrxzrvdyht.com/]gulrxzrvdyht[/url], [link=http://eluhvxdznmas.com/]eluhvxdznmas[/link], http://huvditbryfga.com/
  • 游客『Valentin』于2018-3-31 12:52:58发表评论:
  • 评分: 3分
    Could I make an appointment to see ? <a href=" http://louwilliamsfoundation.com/index.php?order-bathmate-by-phone#helpful ">bathmate results review</a>  He knew if the commissioner hadn’t already seen it, he would see it.’”
     <a href=" http://ato-nh.nl/promethazine-syrup-for-babies/ ">phenergan dosage in infants</a>  policy is about to tighten — will put it off for a while longer.The Bank of Japan maintained its massive stimulus programme earlier and cut its inflation outlook, suggesting there may be more to come.
  • 游客『Eric』于2018-3-31 11:10:07发表评论:
  • 评分: 3分
    How do you do? <a href=" http://ashimages.co.uk/erectile-dysfunction-over-the-counter-meds-remedies-options.htm#settlement ">erectile dysfunction treatment otc replacement</a>  It now comprises Fosun with a 62.6percent stake, Portuguese insurer Fidelidade with 20 percent,French private equity partner Ardian with 5.8 percent, themanagement of Club Med with 2.9 percent and Chinese travelagency U-Tour with 8.7 percent.
     <a href=" http://www.authentichubbard.org/dosis-obat-ketoconazole-tablet.htm#primary ">buy ketoconazole shampoo australia</a>  Understanding more about what life is really like for these men is crucial if we are to make sure all men with prostate cancer can make truly informed treatment choices, and achieve the best possible quality of life during and after their care," commented Dr Sarah Cant, director of policy and strategy at Prostate Cancer UK, which funded the study along with the Health Research Board.
  • 游客『Gabriella』于2018-3-31 9:27:33发表评论:
  • 评分: 3分
    I'm a member of a gym <a href=" http://lodgehope337.org.uk/can-you-buy-alka-seltzer-in-australia/ ">where can i find alka seltzer gold</a>  For instance we tend to think of Sherlock Holmes and Dr Watson stumbling around in a thick pall of London fog
     <a href=" http://generatorgear.com/side-effects-of-trazodone-hcl-50-mg.html#elsewhere ">trazodone online uk</a>  Guinea, the first country to detect the virus, previously said it was containing the outbreak but announced that nine new cases had been found in the prefecture of Kerouane, some 750 km (470 miles) southeast of the capital Conakry.
    查看关于此文章的所有评论
    Address: Address: No.11, Dongfang East Road, Chaoyang District, Beijing, China China Post code: 100191
    Tel:00400-810-0881 0086-10-8441 5678    Fax:0086-10-84415679    京ICP备06004786号

    trade trade Rhinestone Jewelry business trade wholesale clothing lawyer Rhinestone Jewelry